Event-Driven Stocks

BiomX Inc.

PHGENYSE

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue——————
Operating income−$41.5M−$44.5M−$25.3M−$27.2M−$35.5M−$30.3M
Net income−$36.2M−$17.7M−$26.2M−$28.3M−$36.2M−$30.1M
Total assets$5.8M$43.2M$25.0M$45.5M$78.0M$70.4M
Total liabilities——————
Equity−$1.3M$24.1M$3.1M$21.0M$47.5M$57.5M
EPS (diluted)$22.19$58.31$0.51$0.95$1.39—
Shares out.25.0M55.2M33.2M29.8M24.2M22.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
2780.3%
Return on assets
−626.0%
Return on capital (ROCE)
—
Liabilities / assets
—
Debt / equity
—
Book value / share
$-0.05
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−169.6%clean
Piotroski F-Score
2/6weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
46
/ 100
Profitability 50Growth n/aCatalyst 67Earnings quality 67Financial strength 0

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 1 warning● 2 good
  • Negative shareholder equity
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
4 acquisitions0 disposalsnet +898,142 shares · last 4
InsiderDateTypeSharesPrice
Yeganeh ReuvenDirectorMar 16, 2026Conversion450,000$2.00
Yeganeh ReuvenDirectorMar 11, 2026Conversion300,000$2.00
Wolfson MarinaOfficer — Chief Financial OfficerApr 14, 2025Grant68,545$0.00
Bassan MeravOfficer — Chief Development OfficerApr 14, 2025Grant79,597$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026197,5321.0+116.4%
Apr 30, 202691,2801.0+16.7%
Apr 15, 202678,1981.0-9.1%
Mar 31, 202686,0101.1-7.5%
Mar 13, 202693,0101.0-3.4%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)